Cargando…

Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus

The 2013–2016 Ebola virus (EBOV) outbreak in West Africa and the ongoing cases in the Democratic Republic of the Congo have spurred development of a number of medical countermeasures, including rapid Ebola diagnostic tests. The likelihood of transmission increases as the disease progresses due to in...

Descripción completa

Detalles Bibliográficos
Autores principales: DeMers, Haley L., He, Shihua, Pandit, Sujata G., Hannah, Emily E., Zhang, Zirui, Yan, Feihu, Green, Heather R., Reyes, Denise F., Hau, Derrick, McLarty, Megan E., Altamura, Louis, Taylor-Howell, Cheryl, Gates-Hollingsworth, Marcellene A., Qiu, Xiangguo, AuCoin, David P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608863/
https://www.ncbi.nlm.nih.gov/pubmed/33141837
http://dx.doi.org/10.1371/journal.pntd.0008817
_version_ 1783604917946023936
author DeMers, Haley L.
He, Shihua
Pandit, Sujata G.
Hannah, Emily E.
Zhang, Zirui
Yan, Feihu
Green, Heather R.
Reyes, Denise F.
Hau, Derrick
McLarty, Megan E.
Altamura, Louis
Taylor-Howell, Cheryl
Gates-Hollingsworth, Marcellene A.
Qiu, Xiangguo
AuCoin, David P.
author_facet DeMers, Haley L.
He, Shihua
Pandit, Sujata G.
Hannah, Emily E.
Zhang, Zirui
Yan, Feihu
Green, Heather R.
Reyes, Denise F.
Hau, Derrick
McLarty, Megan E.
Altamura, Louis
Taylor-Howell, Cheryl
Gates-Hollingsworth, Marcellene A.
Qiu, Xiangguo
AuCoin, David P.
author_sort DeMers, Haley L.
collection PubMed
description The 2013–2016 Ebola virus (EBOV) outbreak in West Africa and the ongoing cases in the Democratic Republic of the Congo have spurred development of a number of medical countermeasures, including rapid Ebola diagnostic tests. The likelihood of transmission increases as the disease progresses due to increasing viral load and potential for contact with others. Early diagnosis of EBOV is essential for halting spread of the disease. Polymerase chain reaction assays are the gold standard for diagnosing Ebola virus disease (EVD), however, they rely on infrastructure and trained personnel that are not available in most resource-limited settings. Rapid diagnostic tests that are capable of detecting virus with reliable sensitivity need to be made available for use in austere environments where laboratory testing is not feasible. The goal of this study was to produce candidate lateral flow immunoassay (LFI) prototypes specific to the EBOV glycoprotein and viral matrix protein, both targets known to be present during EVD. The LFI platform utilizes antibody-based technology to capture and detect targets and is well suited to the needs of EVD diagnosis as it can be performed at the point-of-care, requires no cold chain, provides results in less than twenty minutes and is low cost. Monoclonal antibodies were isolated, characterized and evaluated in the LFI platform. Top performing LFI prototypes were selected, further optimized and confirmed for sensitivity with cultured live EBOV and clinical samples from infected non-human primates. Comparison with a commercially available EBOV rapid diagnostic test that received emergency use approval demonstrates that the glycoprotein-specific LFI developed as a part of this study has improved sensitivity. The outcome of this work presents a diagnostic prototype with the potential to enable earlier diagnosis of EVD in clinical settings and provide healthcare workers with a vital tool for reducing the spread of disease during an outbreak.
format Online
Article
Text
id pubmed-7608863
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-76088632020-11-05 Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus DeMers, Haley L. He, Shihua Pandit, Sujata G. Hannah, Emily E. Zhang, Zirui Yan, Feihu Green, Heather R. Reyes, Denise F. Hau, Derrick McLarty, Megan E. Altamura, Louis Taylor-Howell, Cheryl Gates-Hollingsworth, Marcellene A. Qiu, Xiangguo AuCoin, David P. PLoS Negl Trop Dis Research Article The 2013–2016 Ebola virus (EBOV) outbreak in West Africa and the ongoing cases in the Democratic Republic of the Congo have spurred development of a number of medical countermeasures, including rapid Ebola diagnostic tests. The likelihood of transmission increases as the disease progresses due to increasing viral load and potential for contact with others. Early diagnosis of EBOV is essential for halting spread of the disease. Polymerase chain reaction assays are the gold standard for diagnosing Ebola virus disease (EVD), however, they rely on infrastructure and trained personnel that are not available in most resource-limited settings. Rapid diagnostic tests that are capable of detecting virus with reliable sensitivity need to be made available for use in austere environments where laboratory testing is not feasible. The goal of this study was to produce candidate lateral flow immunoassay (LFI) prototypes specific to the EBOV glycoprotein and viral matrix protein, both targets known to be present during EVD. The LFI platform utilizes antibody-based technology to capture and detect targets and is well suited to the needs of EVD diagnosis as it can be performed at the point-of-care, requires no cold chain, provides results in less than twenty minutes and is low cost. Monoclonal antibodies were isolated, characterized and evaluated in the LFI platform. Top performing LFI prototypes were selected, further optimized and confirmed for sensitivity with cultured live EBOV and clinical samples from infected non-human primates. Comparison with a commercially available EBOV rapid diagnostic test that received emergency use approval demonstrates that the glycoprotein-specific LFI developed as a part of this study has improved sensitivity. The outcome of this work presents a diagnostic prototype with the potential to enable earlier diagnosis of EVD in clinical settings and provide healthcare workers with a vital tool for reducing the spread of disease during an outbreak. Public Library of Science 2020-11-03 /pmc/articles/PMC7608863/ /pubmed/33141837 http://dx.doi.org/10.1371/journal.pntd.0008817 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
DeMers, Haley L.
He, Shihua
Pandit, Sujata G.
Hannah, Emily E.
Zhang, Zirui
Yan, Feihu
Green, Heather R.
Reyes, Denise F.
Hau, Derrick
McLarty, Megan E.
Altamura, Louis
Taylor-Howell, Cheryl
Gates-Hollingsworth, Marcellene A.
Qiu, Xiangguo
AuCoin, David P.
Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus
title Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus
title_full Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus
title_fullStr Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus
title_full_unstemmed Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus
title_short Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus
title_sort development of an antigen detection assay for early point-of-care diagnosis of zaire ebolavirus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608863/
https://www.ncbi.nlm.nih.gov/pubmed/33141837
http://dx.doi.org/10.1371/journal.pntd.0008817
work_keys_str_mv AT demershaleyl developmentofanantigendetectionassayforearlypointofcarediagnosisofzaireebolavirus
AT heshihua developmentofanantigendetectionassayforearlypointofcarediagnosisofzaireebolavirus
AT panditsujatag developmentofanantigendetectionassayforearlypointofcarediagnosisofzaireebolavirus
AT hannahemilye developmentofanantigendetectionassayforearlypointofcarediagnosisofzaireebolavirus
AT zhangzirui developmentofanantigendetectionassayforearlypointofcarediagnosisofzaireebolavirus
AT yanfeihu developmentofanantigendetectionassayforearlypointofcarediagnosisofzaireebolavirus
AT greenheatherr developmentofanantigendetectionassayforearlypointofcarediagnosisofzaireebolavirus
AT reyesdenisef developmentofanantigendetectionassayforearlypointofcarediagnosisofzaireebolavirus
AT hauderrick developmentofanantigendetectionassayforearlypointofcarediagnosisofzaireebolavirus
AT mclartymegane developmentofanantigendetectionassayforearlypointofcarediagnosisofzaireebolavirus
AT altamuralouis developmentofanantigendetectionassayforearlypointofcarediagnosisofzaireebolavirus
AT taylorhowellcheryl developmentofanantigendetectionassayforearlypointofcarediagnosisofzaireebolavirus
AT gateshollingsworthmarcellenea developmentofanantigendetectionassayforearlypointofcarediagnosisofzaireebolavirus
AT qiuxiangguo developmentofanantigendetectionassayforearlypointofcarediagnosisofzaireebolavirus
AT aucoindavidp developmentofanantigendetectionassayforearlypointofcarediagnosisofzaireebolavirus